UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
August 8, 2014
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
|
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
|
Yes [ ]
|
No [X]
|
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________
Trading in Novo Nordisk shares by board members, executives and associated persons on 7 August 2014
Bagsvaerd, Denmark, 8 August 2014 In accordance with Section 28a of the Danish Securities Trading Act, the company’s board members and executives have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons as reported by those persons to Novo Nordisk.
Please find below a statement of such trading in shares issued by Novo Nordisk.
|
Name
|
Liz Hewitt
|
|
Reason for reporting
|
Member of the Board of Directors
|
|
Financial instrument and ID code
|
Novo Nordisk B DK0060534915
|
|
Type of transaction
|
Purchase of shares
|
|
Date of transaction
|
7 August 2014
|
|
Place of transaction
|
NASDAQ OMX Copenhagen
|
|
Volume of transaction
|
725 shares
|
|
Total value of transaction
|
DKK 185,455
|
Page 2 of 4
|
Name
|
Adam Munk Riis
|
|
Reason for reporting
|
Associated to a member of Executive Management, Jakob Riis
|
|
Financial instrument and ID code
|
Novo Nordisk B DK0060534915
|
|
Type of transaction
|
Purchase of shares
|
|
Date of transaction
|
7 August 2014
|
|
Place of transaction
|
NASDAQ OMX Copenhagen
|
|
Volume of transaction
|
472 shares
|
|
Total value of transaction
|
DKK 118,802
|
|
Name
|
Carl Munk Riis
|
|
Reason for reporting
|
Associated to a member of Executive Management, Jakob Riis
|
|
Financial instrument and ID code
|
Novo Nordisk B DK0060534915
|
|
Type of transaction
|
Purchase of shares
|
|
Date of transaction
|
7 August 2014
|
|
Place of transaction
|
NASDAQ OMX Copenhagen
|
|
Volume of transaction
|
472 shares
|
|
Total value of transaction
|
DKK 118,802
|
Page 3 of 4
|
Name
|
Elsemarie Munk Riis
|
|
Reason for reporting
|
Associated to a member of Executive Management, Jakob Riis
|
|
Financial instrument and ID code
|
Novo Nordisk B DK0060534915
|
|
Type of transaction
|
Purchase of shares
|
|
Date of transaction
|
7 August 2014
|
|
Place of transaction
|
NASDAQ OMX Copenhagen
|
|
Volume of transaction
|
472 shares
|
|
Total value of transaction
|
DKK 118,850
|
Definitions and background information:
Publication
Publication shall take place no later than two working days after the trading by board members or executives or notification of trading by associated persons. Publication is only required when the total amount of transactions of a specific board member/executive and his/her associated persons in any one calendar year has reached 5,000 euros.
Who are board members, executives and associated persons?
Board members and executives are members of the Board of Directors and Executive Management, respectively, of Novo Nordisk A/S. Associated persons are defined as the following persons associated to a board member/executive: 1) spouse or cohabitant, 2) children under the age of 18 years, 3) relatives defined as brothers, sisters, parents, grandparents etc, children, grandchildren etc who have shared the same household with a board member/executive for at least one year, and 4) any legal person, including a company, a foundation or a partnership, which is controlled directly or indirectly by a board member/executive and/or a person mentioned in 1)–3), or to which a board member/executive and/or a person mentioned in 1)–3) has managerial responsibilities or economic interests substantially equivalent to the legal person.
What is trading/transaction?
Trading is any kind of transaction, including shares purchased or otherwise acquired, shares sold or otherwise disposed, gifts, mortgages and grants and exercise of options, but not heritage.
Page 4 of 4
What is financial instrument and ID code?
Financial instrument includes shares listed on the NASDAQ OMX Copenhagen and ADRs listed on New York Stock Exchange, except for ADRs held in 401(k) retirement plan by US-based employees. The ID code is the code (ISIN DK0060534915) of the Novo Nordisk share on the NASDAQ OMX Copenhagen or the code (NVO) on New York Stock Exchange.
What is date and place of transaction?
Date of transaction is the actual transaction date. The place of transaction is the actual place of transaction, ie NASDAQ OMX Copenhagen or New York Stock Exchange.
What is volume and value of transaction?
The volume of transaction is the number of shares (of DKK 0.20 nominal value) or other financial instruments traded. The transaction value is the number of shares traded multiplied by the transaction price. The exchange rate of the Danish Central Bank (Nationalbanken) on the date of transaction is used for calculating the transaction value in DKK in case of ADRs listed on New York Stock Exchange.
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 40,700 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.
|
Further information
|
||
|
Media:
|
||
|
Anne Margrethe Hauge
|
+45 4442 3450
|
amhg@novonordisk.com
|
|
Ken Inchausti (US)
|
+1 609 514 8316
|
kiau@novonordisk.com
|
| Investors: | ||
|
Kasper Roseeuw Poulsen
|
+45 3079 4303
|
krop@novonordisk.com
|
|
Jannick Lindegaard Denholt
|
+45 3079 8519
|
jlis@novonordisk.com
|
|
Daniel Bohsen
|
+45 3079 6376
|
dabo@novonordisk.com
|
|
Frank Daniel Mersebach (US)
|
+1 609 235 8567
|
fdni@novonordisk.com
|
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
24 25 67 90
|
|
Company announcement No 49 / 2014
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
|
Date: August 8, 2014
|
NOVO NORDISK A/S
Lars Rebien Sørensen,
Chief Executive Officer
|